Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
Swiss pharma giant Novartis AG NVS reported better-than-expected results for the first quarter of 2025 and upped its annual guidance.
Core earnings (excluding one-time charges) of $2.28 per share easily beat the Zacks Consensus Estimate of $2.12 and were up from $1.80 reported a year ago. The year-over-year improvement was driven by strong growth in sales. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Revenues of $13.23 billion climbed 12% from the year-ago reported figure. On a constant currency basis, sales increased 15%, driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Leqvio and Scemblix. The top line comfortably beat the Zacks Consensus Estimate of $12.9 billion.
Shares are up in pre-market trading in response to the strong quarterly results and increased guidance.
Shares of Novartis have gained 18.4% year to date compared with the industry's growth of 1.6%.
Image Source: Zacks Investment Research
All growth rates mentioned below are on a year-over-year basis and at constant exchange rates.
With the successful spin-off of the Sandoz business in 2023, Novartis now concentrates on four core therapeutic areas — cardiovascular-renal-metabolic, immunology, neuroscience and oncology.
Cardiovascular drug Entresto's sales rose 22% from the year-ago level to $2.26 billion. The increase was driven by robust, demand-led growth globally, including China and Japan, with increased penetration in hypertension.
Entresto's sales comfortably beat the Zacks Consensus Estimate of $2.25 billion and our model estimate of $2.2 billion.
Cosentyx's sales (psoriasis, spondylitis and arthritis) increased 18% to $1.53 billion, which missed the Zacks Consensus Estimate of $1.57 billion and our model estimate of $1.6 billion. The year-over-year improvement was driven by recent launches, including the hidradenitis suppurativa indication (HS) and the intravenous formulation (IV) in the United States, and volume growth in core indications.
Kisqali (breast cancer) maintained its stellar performance, with sales surging 56% to $956 million. Sales grew strongly across all regions, driven by exemplary growth in the United States with strong momentum from the recently launched early breast cancer (eBC) indication as well as continued share gains in the metastatic breast cancer indication.
Kisqali sales beat both the Zacks Consensus Estimate and our model estimate of $936 million.
Kesimpta (multiple sclerosis) sales totaled $899 million, which rose 43% on increased demand. The figure beat the Zacks Consensus Estimate of $872 million and our model estimate of $875 million.
Strong performances by Tafinlar + Mekinist (up 19% to $552 million) and Jakavi (up 7% to $492 million) also boosted the top line.
Promacta sales totaled $546 million, up 8%.
Xolair (asthma and allergies) sales grew 19% year over year to $456 million, driven by the chronic spontaneous urticaria indication, with a strong contribution from emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair in the United States.
Ilaris sales amounted to $419 million, which increased 20% year over year, driven by growth in all regions led by the United States and Europe.
Tasigna sales declined 2% to $377 million due to lower demand and increasing competition.
Pluvicto (prostate cancer) raked in sales of $371 million, up 21% on solid growth in the United States and Europe in the metastatic castration-resistant prostate cancer (mCRPC) post-taxane setting.
The FDA's approval for earlier use of the drug before chemotherapy will approximately triple the eligible patient population.
Sales missed the Zacks Consensus Estimate of $381 million and our estimate of $385.7 million.
Gene-therapy Zolgensma (spinal muscular atrophy) sales of $327 million were up 13%.
Cholesterol drug Leqvio sales soared 72% to $257 million on steady growth in demand. The figure beat the Zacks Consensus Estimate of $243 million and our estimate of $244 million.
Scemblix sales surged 76% to $238 million, driven by continued growth in chronic myeloid leukemia indication and strong momentum from the recently launched early-line indication in the United States.
Luthathera (cancer) sales totaled $193 million, up 15%. Sales grew mainly in the United States, Europe and Japan due to increased demand and earlier line adoption, particularly in the United States and Japan.
Sales of Lucentis plunged 38% to $189 million due to generic competition.
Fabhalta generated sales of $81 million, driven by continued launch execution across all markets in PNH and the recent launch in IgAN in the United States.
Net sales are now expected to grow in high single digits (previous guidance: mid to high single digits). Core operating income is now expected to grow in low double-digits (previous guidance: high single to low double digits).
The FDA expanded Pluvicto's label to include patients with PSMA-positive mCRPC who have been treated with an androgen receptor pathway inhibitor and are considered appropriate to delay chemotherapy, approximately tripling the eligible patient population.
The regulatory body also granted accelerated approval for Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Fabhalta was approved by the FDA, European Commission and China's regulatory body for adult patients with C3 glomerulopathy (C3G), making it the first and only treatment approved for this condition in all three markets.
Novartis' performance in the first quarter was impressive, with both earnings and sales beating estimates. Consequently, management raised its guidance for 2025, driven by strong growth of priority drugs, such as Leqvio, Kisqali and Kesimpta, during the first quarter.
Novartis AG price-consensus-eps-surprise-chart | Novartis AG Quote
Novartis' performance has been pretty good in the past few quarters, buoyed by the solid performance of its priority brands. An increase in guidance implies that this momentum will be sustained in the upcoming quarters.
The pipeline progress is also encouraging. The label expansion of Pluvicto and Fabhalta should further fuel sales of these drugs. Approval of new drugs and label expansion of existing drugs should enable the company to offset the adverse impacts from expected generic competition for Tasigna, Promacta and Entresto (mid-2025).
While organic growth continues to drive business, NVS is focused on strategic bolt-in acquisitions to strengthen its pipeline. The company acquired Anthos Therapeutics, a clinical-stage biopharmaceutical company, to broaden its cardiovascular portfolio. The acquisition added abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Earlier, Novartis entered into a global license and collaboration agreement with PTC Therapeutics for the latter's Huntington's disease candidate to strengthen NVS' neuroscience pipeline.
Meanwhile, NVS recently announced a planned $23 billion investment over five years in U.S.-based infrastructure as it intends to manufacture all key drugs in the country. NVS' decision to expand its current manufacturing, research and technology presence across the country follows President Trump's announcement of tariffs on pharmaceutical imports.
Novartis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked large-cap pharmaceutical stocks are Bayer BAYRY and Pfizer PFE, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Bayer's 2025 earnings per share (EPS) have increased to $1.19 from $1.14. During the same time, EPS estimate for 2026 has increased to $1.28 from $1.123. Year to date, shares of Bayer have surged 34.6%.
Estimates for Pfizer's 2025 EPS have risen from $2.96 to $2.99 over the past 60 days. Estimates for 2026 EPS have risen from $2.99 to $3.02 over the same timeframe. Pfizer beat on earnings in each of the trailing four quarters, delivering an average surprise of 4.16%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
UBS faces $26B in capital requirements from Swiss bank reforms, Bloomberg says
UBS (UBS) is facing as much as $26B in capital requirements to be phased over the next decade under banking reform proposals from the Swiss government, Bastian Benrath-Wright and Noele Illien of Bloomberg reports. The largest hit to the bank is set to come from a proposal that would require the company to increase the capital held at home against its stakes in foreign units to 100% from the current 60%. The government estimates this will force UBS to add as much as $23B in capital to its Swiss-based main unit. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on UBS: Disclaimer & DisclosureReport an Issue UBS Lowers Price Target on Berkshire Hathaway Stock (BRK.B) as 'Buffett Premium' Ends UBS Group AG Faces Sell Rating Amid Regulatory Uncertainty and Capital Challenges UBS call volume above normal and directionally bullish UBS upgraded to Buy from Hold at Jefferies Unusually active option classes on open May 27th Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Lemonade (LMND) Reports Q1 Earnings: What Key Metrics Have to Say
Lemonade (LMND) reported $151.2 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 27%. EPS of -$0.86 for the same period compares to -$0.67 a year ago. The reported revenue represents a surprise of +5.05% over the Zacks Consensus Estimate of $143.93 million. With the consensus EPS estimate being -$0.94, the EPS surprise was +8.51%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Lemonade performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: In force premium (end of period): $1.01 billion compared to the $999.35 million average estimate based on four analysts. Premium per Customer (end of period): $396 versus $394.15 estimated by four analysts on average. Customers (end of period): 2,545,496 versus the four-analyst average estimate of 2,535,658. Net loss ratio: 82% versus the four-analyst average estimate of 89%. Gross loss ratio: 78% compared to the 80.8% average estimate based on four analysts. Net investment income: $9.50 million versus the four-analyst average estimate of $8.45 million. The reported number represents a year-over-year change of +25%. Ceding commission income: $26.90 million versus $22.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +28.1% change. Commission income: $10.50 million versus the four-analyst average estimate of $8.02 million. The reported number represents a year-over-year change of +72.1%. Net earned premium: $104.30 million compared to the $105.18 million average estimate based on four analysts. The reported number represents a change of +23.6% year over year. View all Key Company Metrics for Lemonade here>>>Shares of Lemonade have returned +6.7% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lemonade, Inc. (LMND) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 days ago
- Yahoo
After its data was wiped, KiranaPro's co-founder cannot rule out an external hack
Indian grocery delivery startup KiranaPro's recent data loss story has more holes than Swiss cheese, as the startup remains unclear whether the incident was an internal breach or an external hack. Last week, the Bengaluru-based startup discovered that it could not access its back-end servers and that all its data, including its app code, had been deleted from GitHub. The startup on Friday blamed a former employee for the breach. However, in an interview, KiranaPro co-founder and CEO Deepak Ravindran conceded that the company had not deactivated the employee's account after they departed the company and cannot rule out the possibility of subsequent malicious misuse of their account. "If we go deeper, we have to do a real forensic investigation. We are going to talk [about] this with our board, the investors, and we are going to get a formal opinion on that also with our legal advisers," Ravindran told TechCrunch. Earlier on Friday, Ravindran claimed in a post on X that the incident that affected its data was an internal breach. "After careful investigation, we conclude that this was not a hack. No external party penetrated our ordering or payment systems, exploited vulnerabilities, or bypassed security protocols," he wrote. The co-founder also explicitly shared a screenshot of a LinkedIn profile of one of KiranaPro's former employees on X on Thursday, alleging that they had deleted the startup's code. (TechCrunch is not sharing the post's link, as the startup has yet to offer concrete proof supporting its position.) "[T]his was an internal data breach. Specifically, it was the result of actions taken by a trusted internal employee who had legitimate access to our systems," the co-founder wrote in his post on Friday. "This individual intentionally deleted critical server logs while they were being tested and/or edited, an action that goes directly against our policies, our principles, and the trust we place in our team." When TechCrunch asked if KiranaPro could rule out whether any third party had maliciously gained access to the former employee's account, Ravindran could not. "We have to do a complete forensic check on the company. We have to do the entire IP scan. We have to look at where the tracks happened. We have to check the computers, MacBooks, and whatever is used. Everything has to be done. Then we have to spend money … so, that's why we decided not to," he told TechCrunch. Then what was the basis of Ravindran's allegation? It was a GitHub response, a copy of which he shared with TechCrunch. The response included a username, which Ravindran said was associated with the former employee. "All we have is the emails that we got from GitHub, stating that [the former employee's username] as an individual is the one who deleted the account. We haven't done the investigation further," Ravindran told TechCrunch. Launched in late 2024, KiranaPro operates as a buyer app on the Indian government's Open Network for Digital Commerce. The startup allows more than 55,000 customers in 50 cities to purchase groceries from their local shops and nearby supermarkets using its voice-based interface. The company also supports local language inputs, including English, Hindi, Malayalam, and Tamil. Ravindran stated that they decided to call out the former employee based on the company's "belief system," as they claim the former employee deleted the data after their sudden termination. However, the startup said it is not aware if there were enough protections on the former employee's devices, such as multi-factor authentication, to restrict malicious third-party access, like malware. The company confirmed it did not remove the employee's access to its data and GitHub account following his departure. "Employee offboarding was not being handled properly because there was no full-time HR," KiranaPro's chief technology officer, Saurav Kumar, confirmed to TechCrunch. Alongside its code saved in GitHub, KiranaPro also lost access to its Amazon Web Services (AWS) account, which included its customer data and their transaction details. Ravindran told TechCrunch that the GitHub data was restored after getting its backup from one of their employees. The startup also regained access to its AWS account along with its customer data. Both the co-founder and CTO said the AWS account was protected by multi-factor authentication, but neither could say how the account was accessed, as nobody else had physical access to Ravindran's phone, which generates the multi-factor code. Nonetheless, Ravindran claimed that the customer data stored in the AWS cloud remained intact and was not accessed by any third parties, nor was it downloaded by the former employee in question. "Because if that is the case, I will get its notification on email or anything [sic]," he said. That said, Ravindran stated that the startup has enough evidence to file a formal complaint with the police, but said that its investigation is ongoing. The startup has also not fully paid its current employees, the company's co-founder confirmed, soon after the company raised a seed round of ₹100 million Indian rupees (about $1.2 million), which Ravindran said has yet to be fully wired. The startup counts Blume Ventures, Unpopular Ventures, and Turbostart among its institutional venture backers, as well as Olympic medalist PV Sindhu and Boston Consulting Group managing director Vikas Taneja among its angel investors. It has 15 employees located in Bengaluru and Kerala. Sign in to access your portfolio
